AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15766375
Drug: 0.12% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% CHX non-alcohol base with 0.05% cetyl pyridinium chloride (Cpc) mouthrinse (Perioaid), 15 ml, twice daily for 30 s
Trial: 15766375
Drug: 0.2% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% CHX alcohol base (Corsodyl), 10 ml, twice daily for 60 s
Trial: 11982617
Drug: Daclizumab 1
RxNorm normalized name: daclizumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 1 mg/kg/dose every 14 d for five doses (Group I)
Trial: 11982617
Drug: Daclizumab 2
RxNorm normalized name: daclizumab 25 MG per 5 ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 2 mg/kg/dose every 14 d for two doses (Group II)
Trial: 11982617
Drug: No antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibody induction (Group III)
Trial: 2113567
Drug: Thyrotropin‐releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin‐releasing hormone (TRH) (200 micrograms iv)
Trial: 2113567
Drug: Apomorphine HCl
RxNorm normalized name: apomorphine HCl
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apomorphine HCl (Apo) (0.5 mg sc)
Trial: 31124887
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg i.v. dexamethasone
Trial: 27978548
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1200 mg elemental calcium)
Trial: 23691925
Drug: Family group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family group psychotherapy (FGP) - 8 monthly sessions
Trial: 17355744
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of valsartan (160 mg) and simvastatin (40 mg)
Trial: 11517998
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX‐A) injections into the calf muscles
Trial: 11517998
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injections (single blind control)
Trial: 3262334
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin plus electric stimulation
Trial: 29658856
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (pemetrexed and a platinum-based drug)
Trial: 29658856
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (pemetrexed and a platinum-based drug)
Trial: 25643246
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) with intravenous narcotics
Trial: 22998533
Drug: Flaxseed (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (40 g/day for 8 weeks)
Trial: 9113256
Drug: m-chlorophenylpiperazine (m-CPP)
RxNorm normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-chlorophenylpiperazine (m-CPP) 0.5 mg/kg orally
Trial: 4061896
Drug: Thiopental (2.5%)
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopental (2.5%) administered at doses of 2, 3, 4, 5, 6, 7, or 8 mg/kg
Trial: 31204610
Drug: Active peer
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active peer modeling intervention, including exercise prescription and information
Trial: 29234038
Drug: Sodium tanshinone
RxNorm normalized name: Tanshinone I
DrugBank: Tanshinone I (DB16886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium tanshinone IIA sulfate (STS) injection (80 mg, once daily for 14 consecutive days)
Trial: 23625305
Drug: Cornus mas
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cornus mas L. supplementation (50 g twice a day)
Trial: 19212897
Drug: Self-initiated exercise
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Self-initiated exercise (no specific therapy recommended)
Trial: 7081139
Drug: Bacillus Calmette‐Guerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette‐Guerin (BCG) adjuvant immunotherapy plus conventional therapy
Trial: 6365474
Drug: Diprolene ointment
RxNorm normalized name: betamethasone Topical Ointment [Diprolene]
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diprolene ointment 0.05 percent (betamethasone dipropionate) applied topically at a fixed dose of 7 gm/day for 14 days (Study 1) or 21 days (Study 2)
Trial: 6365474
Drug: Dermovate ointment
RxNorm normalized name: clobetasol Topical Ointment [Temovate]
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dermovate ointment 0.05 percent (clobetasone propionate) applied topically at a fixed dose of 7 gm/day for 14 days (Study 1) or 21 days (Study 2)
Trial: 31296936
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 supplementation (50 µg per day)
Trial: 22541245
Drug: Budesonide/formoterol pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol pMDI (320/9 μg twice-daily)
Trial: 22541245
Drug: Budesonide pMDI
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide pMDI (320 μg twice-daily)
Trial: 19548011
Drug: Oral‐B Professional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B Professional Care 8500 (PC 8500)
Trial: 19548011
Drug: Oral‐B CrossAction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B CrossAction Vitalizer (CAV)
Trial: 1524321
Drug: Continuous oscillation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oscillation therapy on the Kinetic Treatment Table
Trial: 1524321
Drug: No continuous
RxNorm normalized name: Lotion, Multi Ingredient Topical application Lotion [AVEENO CONTINUOUS RADIANCE MOISTURIZING LOTION]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No continuous oscillation therapy (Control)
Trial: 6360704
Drug: Fenoterol (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (0.6 mg, pressurized aerosol)
Trial: 6360704
Drug: Fenoterol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (1.0 mg, pressurized aerosol)
Trial: 6360704
Drug: Fenoterol (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (0.6 mg, dry powder)
Trial: 6360704
Drug: Fenoterol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (1.0 mg, dry powder)
Trial: 8557010
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg kg‐1 rocuronium (2 x ED95)
Trial: 8557010
Drug: 0.06 mg
RxNorm normalized name: urea 0.06 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg kg‐1 priming dose followed by 0.24 mg kg‐1 rocuronium
Trial: 7969680
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor treatment
Trial: 31970939
Drug: TAC-302 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC-302 (100 to 1200 mg single dose)
Trial: 31970939
Drug: TAC-302 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC-302 (400 mg single dose)
Trial: 31970939
Drug: TAC-302 (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC-302 (100, 200, or 400 mg multiple doses for 5 days, twice daily)
Trial: 30838446
Drug: Lidocaine 40
RxNorm normalized name: lidocaine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 40 mg (Group L40)
Trial: 30838446
Drug: Lidocaine 20
RxNorm normalized name: lidocaine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 20 mg (Group L20)
Trial: 28817744
Drug: Oral voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral voriconazole (dosage not specified) and topical voriconazole, 1%
Trial: 28817744
Drug: Topical natamycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical natamycin, 5% (added after 39 participants enrolled)
Trial: 22836860
Drug: Intravenous somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous somatostatin
Trial: 21071588
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BR) 0.5 l/day, containing ∼6.2 mmol of NO(3)(‐)
Trial: 21071588
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) 0.5 l/day, containing ∼0.003 mmol of NO(3)(‐)
Trial: 9062599
Drug: 0.5% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% lignocaine 1 mg/kg
Trial: 9062599
Drug: 0.5% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% lignocaine 2 mg/kg
Trial: 9062599
Drug: 0.5% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% lignocaine 2.89 mg/kg
Trial: 8376436
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.5% bupivacaine injection into the wound (n = 30)
Trial: 3740650
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate 2 mg by inhalation
Trial: 3740650
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate 4 mg by inhalation
Trial: 3740650
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate 6 mg by inhalation
Trial: 3740650
Drug: Atropine free
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine free base 1.67 mg by intramuscular injection
Trial: 30547750
Drug: Intense treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intense treatment (four two-weekly standard doses of praziquantel)
Trial: 30547750
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (one standard dose of praziquantel)
Trial: 26858331
Drug: CLND +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLND + High-Dose Interferon Alfa-2b (HDI)
Trial: 15456336
Drug: Single-dose prulifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose prulifloxacin 600 mg
Trial: 29130272
Drug: Formulary change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulary change (addition of a high-potency atorvastatin)
Trial: 25601294
Drug: Exposure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure treatment in three contexts
Trial: 25601294
Drug: Exposure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure treatment in one context
Trial: 23392481
Drug: 3 rounds
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 rounds of annual mass drug administrations (MDAs) with azithromycin
Trial: 8218682
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL immune serum globulin (ISG)
Trial: 8218682
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL immune serum globulin (ISG)
Trial: 3315600
Drug: Hospital administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital administration
Trial: 3315600
Drug: At-home injection
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At-home injection
Trial: 21763099
Drug: Guideline-based drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based drug management
Trial: 16039603
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy/Habit Reversal Training (ACT/HRT)
Trial: 10773501
Drug: Droperidol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (2.5 mg) and fentanyl (0.4 mg) in 40 ml of 0.125% bupivacaine
Trial: 10773501
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.4 mg fentanyl in 40 ml of 0.125% bupivacaine)
Trial: 10773501
Drug: Butorphanol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (2 mg) and fentanyl (0.4 mg) in 40 ml of 0.125% bupivacaine
Trial: 9053816
Drug: Quinapril 20
RxNorm normalized name: quinapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 20 mg once-a-day
Trial: 7953031
Drug: Home-based care
RxNorm normalized name: Gelato Home-Care 1.1 % Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based care (Daily Living Programme, DLP)
Trial: 27905499
Drug: Brain-derived neurotrophic
RxNorm normalized name: brain-derived neurotrophic factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism treatment
Trial: 22883658
Drug: Self-selected music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-selected music during initial radiotherapy treatment
Trial: 22883658
Drug: No music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No music during initial radiotherapy treatment (Control)
Trial: 20550556
Drug: Continued pharmacotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued pharmacotherapy
Trial: 15736890
Drug: Nd:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG laser alone (Group L: 10 pps, 200 mJ for 90 sec, n = 37)
Trial: 15736890
Drug: Local minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local minocycline administration following laser treatment (Group LP, n = 33)
Trial: 15736890
Drug: Povidone‐iodine irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povidone‐iodine irrigation following laser treatment (Group LI, n = 33)
Trial: 1670585
Drug: Interferon-alpha (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (18 mu daily) and zidovudine (600 mg daily)
Trial: 6617065
Drug: Propranolol 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 180 mg/day twice a day
Trial: 6617065
Drug: Propranolol 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 180 mg/day three times a day
Trial: 6617065
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing regimens (twice and three times a day)
Trial: 29978322
Drug: r-batroxobin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-batroxobin (2.5 BU/2.0 mL)
Trial: 29978322
Drug: r-batroxobin (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-batroxobin (5.0 BU/2.0 mL)
Trial: 29978322
Drug: r-batroxobin (10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-batroxobin (10.0 BU/2.0 mL)
Trial: 28531663
Drug: Ketogenic breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketogenic breakfast intervention (50-250 ml medium-chain triglyceride drink + 5-15 g amino acids) after overnight fast during radiotherapy.
Trial: 17447657
Drug: Antidiabetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiabetic treatment with pioglitazone or glimepiride for 26 ± 2 weeks
Trial: 11756064
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Zn/d for 14 d (Z group)
Trial: 11756064
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup and placebo capsule (placebo group)
Trial: 10483386
Drug: IAN/IO injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAN/IO injection followed by repeated IO injection of 0.9 ml of 2% lidocaine with 1:100,000 epinephrine
Trial: 10483386
Drug: IAN/IO injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAN/IO injection followed by mock IO injection
Trial: 8074256
Drug: norfloxacin in
RxNorm normalized name: Product containing norfloxacin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: norfloxacin in a single 800‐mg dose
Trial: 8074256
Drug: norfloxacin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: norfloxacin, 400 mg twice a day for three days
Trial: 8074256
Drug: trimethoprim (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethoprim (160 mg)‐sulfamethoxazole (800 mg) (TMP‐SMX), twice a day for three days
Trial: 8074256
Drug: trimethoprim (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethoprim (160 mg)‐sulfamethoxazole (800 mg) (TMP‐SMX)
Trial: 2530714
Drug: Sulotroban (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulotroban (4 x 800 mg per day)
Trial: 196518
Drug: Sufentanil (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (0.025 mg/70 kg body weight)
Trial: 196518
Drug: Fentanyl (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.25 mg/70 kg body weight)
Trial: 30741684
Drug: LY2599666 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2599666 10 mg
Trial: 30741684
Drug: LY2599666 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2599666 25 mg
Trial: 30741684
Drug: LY2599666 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2599666 100 mg
Trial: 30741684
Drug: LY2599666 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2599666 200 mg
Trial: 30741684
Drug: LY2599666 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2599666 25 mg once-weekly for 12 weeks
Trial: 19014837
Drug: LC15-0444 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC15-0444 (various doses 25, 50, 100, 200, 400, 600 mg)
Trial: 9226432
Drug: Chewing gum
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewing gum containing 2 mg zinc acetate
Trial: 9226432
Drug: Chewing gum
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewing gum containing 0.5 mg zinc acetate
Trial: 9226432
Drug: Chewing gum
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewing gum containing 0 mg zinc acetate
Trial: 27729579
Drug: Enalapril 10-mg
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10-mg and folic acid 0.8-mg tablet
Trial: 27729579
Drug: Enalapril 10-mg
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10-mg tablet alone
Trial: 18773156
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg/d) plus Ezetimibe (10 mg/d)
Trial: 16182346
Drug: Individualized dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized dosage of 20 ml PCC based on target-INR of 2.1 or 1.5, initial-INR, and patient's body weight (group B)
Trial: 16182346
Drug: Standard dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosage of 20 ml PCC equivalent to about 500 IU factor IX (group A)
Trial: 10984002
Drug: Pramipexole (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (mean dose 0.70 mg/d, mean duration 24.4 weeks)
Trial: 8791959
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g mesalazine in 30 mL (group I, n = 10)
Trial: 8791959
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g mesalazine in 60 mL (group II, n = 12)
Trial: 8791959
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g mesalazine in 100 mL (group III, n = 9)
Trial: 1612319
Drug: Erythromycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (3 mg/kg) administered IV for 15 minutes
Trial: 1612319
Drug: Saline administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administered IV for 15 minutes
Trial: 6368353
Drug: Intensified conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified conventional insulin treatment (CIT)
Trial: 29747810
Drug: Intense care
RxNorm normalized name: Glycerin 1.0 g in 45 g TOPICAL CREAM [TONYMOLY INTENSE CARE SNAIL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intense care of oral hygiene (powered toothbrush and 1% chlorhexidine oral gel)
Trial: 29747810
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care of oral hygiene (manual toothbrush and toothpaste)
Trial: 26963601
Drug: Group Behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Behavioral Couples Therapy (G‐BCT) plus 12-step-oriented Individually Based Therapy (IBT)
Trial: 26963601
Drug: Standard Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Behavioral Couples Therapy (S‐BCT) plus Individually Based Therapy (IBT)
Trial: 18622068
Drug: Preemptive tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive tramadol (iv injection of tramadol 100 mg 15 min before operation)
Trial: 18622068
Drug: Preventive tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive tramadol (same dose of tramadol 100 mg 15 min before the end of the operation)
Trial: 7789488
Drug: Protriptyline 10
RxNorm normalized name: protriptyline 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protriptyline 10 mg daily